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PENGENALPASTIAN MEKANISMA FRAKSI-KAYA BAICALEIN DARI 




Oroxylum indicum (O. indicum) telah diimplikasikan sebagai ajen anti-
kanser untuk rawatan kanser termasuk kanser servik. Kajian terdahulu telah 
menunjukkan kebolehan tumbuhan ini dalam merencat proliferasi sel kanser dengan 
mengaruh apoptosis. Ciri-ciri terapeutik anti-kanser oleh O. indicum sangat berkait 
dengan kandungan kimia utamanya seperti chrysin, oroxylin A dan baicalein. Dalam 
kajian ini, fraksi-kaya baicalein (BRF) daripada daun O. indicum telah diekstrak 
untuk mengenalpasti aktiviti anti-kansernya terhadap sel kanser servik, SiHa (positif 
HPV 16) dan HeLa (positif HPV 18). Dengan menggunakan kaedah kromatografi 
lapisan nipis persediaan (PTLC) (n-hexane: ethyl acetate; 50:50), fraksi ini telah 
disediakan daripada ekstrak metanol dan diteruskan kepada kromatografi cecair 
berprestasi tinggi (HPLC) untuk kuantifikasi baicalein. Aktiviti anti-proliferasi oleh 
BRF telah diuji menggunakan asai metilina biru (MBA). Seterusnya, aktiviti pro-
apoptosis oleh BRF dalam memodulasi ekspresi protein telah ditentukan melalui 
analisis pemblotan Western ke atas ekspresi onkoprotein HPV (E6 dan E7), protein 
penindas tumor (p53 dan pRb) dan protein lain yang penting untuk laluan apoptosis 
melalui pengantaraan mitokondria (Bax, Bcl-2, caspase-9 and caspase-3). 
Selanjutnya, kebergantungan apoptosis yang disebabkan oleh BRF dalam sel kanser 
serviks kepada subfamili protein kinase teraktif-mitogen (MAPK) yang terdiri 
daripada kinase yang terkawal isyarat ekstraselular (ERK), kinase c-Jun N-terminal 




melalui penambahan perencat MAPK yang tertentu. Selain itu, aktiviti pro-apoptosis 
BRF terus dikaji melalui tindakan modulasinya pada ekspresi interleukin (IL)-6 dan 
IL-12 dengan menjalankan asai enzim imunosorben berkaitan enzim (ELISA). 
Hasilnya, BRF dengan 75% baicalein merupakan kompaun yang paling poten 
berbanding cisplatin dan MCE berdasarkan nilai IC50 yang diperolehi daripada 
kedua-dua sel. Selepas 24 jam tempoh rawatan, analisis Western blot menunjukkan 
bahawa sel SiHa dan HeLa yang dirawat dengan BRF telah menurunkan 
pengekspresan E6 dan E7 dan memulihkan aruhan proses apoptosis melalui 
peningkatan pengekspresan p53 dan pRb dalam sel terawat. Dari segi laluan 
apoptosis melalui pengantaraan mitokondria, BRF meningkatkan laluan pengaktifan 
tersebut dengan menurunkan pengekspresan protein anti-apoptosis Bcl-2 dan 
meningkatkan pengekspresan komponen utama seperti Bax, caspase-9 dan caspase-3. 
Bagi isyarat MAPK, aktiviti pro-apoptosis BRF dalam sel SiHa and HeLa didapati 
bergantung kepada MAPK kerana semua subfamilinya terlibat dalam apoptosis yang 
disebabkan oleh BRF secara berbeza. BRF mengaruh apoptosis dalam sel kanser 
serviks melalui perencatan ERK dan pengaktifan JNK. Selain itu, BRF 
meningkatkan pengaktifan Bax melalui laluan ERK/p38 dan menindas ekspresi Bcl-2 
sebahagiannya melalui perencatan ERK dan pengaktifan p38. Sementara itu untuk 
sel HeLa, pengaktifan laluan ERK/JNK/p38 diperlukan untuk mengaktifkan Bax dan 
perencatan kedua-dua isyarat ERK/p38 menggalakkan penurunan kawal atur Bcl-2 
dalam sel HeLa yang dirawat BRF. Aruhan apoptosis oleh BRF juga ditingkatkan 
oleh penurunan pengekspresan IL-6 dan peningkatan kawal atur IL-12. Oleh itu, 
penemuan yang dibentangkan ini telah membuktikan keupayaan BRF yang 
difraksikan daripada daun O. indicum untuk dieksploitasikan sebagai calon anti-




ELUCIDATING THE MECHANISM OF BAICALEIN-RICH FRACTION 
FROM Oroxylum indicum LEAVES ON CERVICAL CANCER CELL LINES 
 
ABSTRACT 
Oroxylum indicum (O. indicum) has been implicated as a promising anti-
cancer agent for cancer treatment including cervical cancer. Previous studies have 
shown that this plant has been able to inhibit the proliferation of cancer cells by 
acting as an apoptosis inducer. The therapeutic anti-cancer properties of O. indicum 
is strongly associated due to its major chemical constituents such as chrysin, oroxylin 
A and baicalein. In this present study, the baicalein-rich fraction (BRF) from O. 
indicum leaves has been extracted to elucidate its anti-cancer activity against cervical 
cancer cells, SiHa (HPV 16 positive) and HeLa (HPV 18 positive) cells. Using the 
preparative thin layer chromatography (PTLC) (n-hexane: ethyl acetate; 50:50), this 
fraction was prepared from the methanol crude extract (MCE) of O. indicum and 
proceeded to high performance liquid chromatography (HPLC) for baicalein 
quantification. At first, anti-proliferative activities of BRF were tested using 
methylene blue assay (MBA). Then, the pro-apoptotic activity of BRF in modulating 
protein expression was determined by Western blot analysis on the expression of 
HPV oncoproteins (E6 and E7), tumour suppressor proteins (p53 and pRb) and key 
proteins of mitochondrial signalling apoptosis pathway (Bax, Bcl-2, caspase-9 and 
caspase-3). Next, the dependency of BRF-induced apoptosis in cervical cancer cells 
to mitogen-activated protein kinase (MAPK) subfamilies consisting of extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 were also 
determined by Western blot analysis with the addition of specific MAPK inhibitors. 




modulation action on the expression of interleukin (IL)-6 and IL-12 by conducting an 
enzyme-linked immunosorbent assay (ELISA). As a result, BRF with 75% of 
baicalein was found to be the most potent compound compared to cisplatin (anti-
cancer drug) and MCE based on the IC50 values obtained from both cells. After 24 
hours treatment period, Western blot analysis showed that BRF-treated SiHa and 
HeLa cells downregulated the expression of E6 and E7 and restored the induction of 
apoptosis process through the up-regulation of p53 and pRb in treated cells. In terms 
of mitochondrial-mediated apoptosis pathway, BRF has positively enhanced the 
activation pathway by downregulating Bcl-2 anti-apoptotic protein and upregulating 
the required key components such as Bax, caspase-9 as well as caspase-3. In regard 
to MAPK signalling cascade, the pro-apoptotic activities of BRF in SiHa and HeLa 
cells have been found to be MAPK-dependent as all its subfamilies involved in BRF-
induced apoptosis but in different approach. BRF induced apoptosis in cervical 
cancer cells predominantly through ERK inhibition and JNK activation. Besides, 
BRF induced Bax activation by ERK/p38 dependent pathway and suppressed Bcl-2 
expression through inhibition of ERK and activation of p38. Meanwhile for HeLa 
cells, activation of ERK/JNK/p38 pathways are required for Bax activation and 
inhibition of both ERK/p38 signalling promoted Bcl-2 downregulation in BRF-
treated HeLa cells. Apoptosis induction by BRF also enhanced through IL-6 
downregulation and IL-12 upregulation. Thus, these presented findings have proved 
the ability of BRF fractionated from O. indicum’s leaves to be exploited as a 







1.1 Background of the study 
 
Cancer has become the major leading cause of death among women 
worldwide in both developing and non-developed countries. Over thousands of 
cancers have been found to date, cervical cancer is one of the most life-threatening 
diseases as it leads to the fourth-largest cause of death among women worldwide, 
especially in low-income countries (Torre et al., 2017). Cervical cancer, also known 
as carcinoma of uterine cervix, remains a major public health concern for women 
throughout the world, despite the existence of efficient prevention and screening 
methods (Koh et al., 2015). The burden of cancer continues to increase in developing 
countries due to the adoption of cancer-associated lifestyles such as smoking, high 
parity and long-term contraceptive use (Torre et al., 2015).  
 
However, the majority of reported cases of cervical cancer resulted from 
human papillomavirus (HPV) infection as HPV deoxyribonucleic acid (DNA) was 
detected in approximately 90% of malignant cervical lesions extracted from cervical 
cancer-positive patients (Petry, 2014). Even though most of HPV infections will be 
cleared by the host defense immune system, however persistent infection with high-
risk group of HPV can contribute to viral immune evasion and allow the 
development of malignant conditions at the infected area of the squamocolumnar 
junction at the cervix tissue lining (Small et al., 2017). High-risk group of HPV; 




cervical cancer with different proportions among global populations (de Martel et al., 
2017).  
 
HPVs are the sexually transmitted viruses and infected under the 
epithelium surface in the basal layer through microwounds as the entrance route. The 
basal layer consist of actively-dividing cells and acts as the reservoir of cells for the 
suprabasal regions (Longworth and Laimins, 2004). Following infection, the life 
cycle of HPV is closely dependent on the differentiation programme of the infected 
host cells as a part of the viral replication strategy. The viral genetic materials will be 
integrated with the host genome, resulting in the lifetime persistence of certain viral 
genes within the cells and causing genomic instability by interfering with the 
regulation of host homeostasis and providing a favourable condition for cancer 
development (Moody and Laimins, 2010).  
 
HPV’s genomic organisation encode for eight proteins with six early 
proteins (E1, E2, E4, E5, E6, E7) and two late proteins (L1 and L2). E2 is a 
replication factor that acts as a viral transcriptional repressor in controlling the 
expression of two main contributor oncoproteins; E6 and E7. The integration of HPV 
genomes into host DNA resulted in the disruption of E2’s open reading frame (ORF) 
and led to the loss of E2 expression, consequently induced uncontrollable cell growth 
due to the overexpression of E6 and E7 (Sasagawa et al., 2012). Although the 
expression of oncoproteins in the basal layer is considered low, the persistent 
infection that continues for years and even decades can certainly accumulate a high 
level of expression of E6 and E7 that is sufficient enough to induce mutation and 




occurred due to the major tumourigenic mechanism of both oncoproteins by 
inactivating the function of tumour suppressor proteins; p53 and retinoblastoma 
protein (pRb) respectively. Abrogation of these key proteins abolish cell proliferation 
control and promote apoptosis evasion in HPV-infected cells (Martinez-zapien et al., 
2016).  
 
Apoptosis is a crucial programme cell death that can be executed via 
several pathways through extracellular and intracellular activation signal (Matsuura 
et al., 2016). Intracellularly, mitochondrial-mediated apoptosis pathway is triggers by 
the interactions between B cell lymphoma (Bcl)-2, Bcl-2-associated X protein (Bax) 
and caspases (Kiraz et al., 2016). In normal condition, cytosolic Bax translocate to 
the mitochondrial membrane and induce pore formation to enable the release of 
cytochrome c. Bcl-2 functions as an antagonist for Bax activities. Next, cytochrome c 
forms an apoptosome complex by associating with apoptosis protease-activating 
factor 1 (Apaf-1). This complex then activates caspase-9 and subsequently leads to 
the activation of caspase-3.  The activated caspase-3 then cleaves myriad of cellular 
proteins to manifest DNA fragmentation as apoptosis representative (Goldar et al., 
2015; Kiraz et al., 2016; Pfeffer and Singh, 2018).  
 
Apoptosis execution can be driven by multiple upstream activators 
including mitogen-activated protein kinase (MAPK) signalling. MAPK is a signal 
transduction cascade that responsible for sustaining human cancer cell survival, 
metastasize and resistance against the chemotherapy drugs (Burotto et al., 2014). 
This complex pathway signals for wide range of cellular activities regulations 




with their respective functions; extracellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38 (Kim and Choi, 2010). ERK was shown to be 
critically important for cell survival meanwhile JNK and p38 were believed as major 
contributors in the regulation of stress-induced apoptosis pathway (Roskoski, 2012; 
Sui et al., 2014). 
 
Apart from that, apoptosis also can be influenced by the imbalance 
secretion of immunoinhibitory and immunostimulatory cytokines. Overexpression of 
immunoinhibitory cytokines such as interleukin (IL)-6 and deprivation of 
immunostimulatory cytokines like IL-12 promotes apoptosis evasion and regularly 
associated with chemoresistance in cancer cells (Carpenter and Lo, 2014; Kursunel 
and Esendagli, 2016; Lin et al., 2017). Due to the link between these mediators with 
apoptosis induction, modulation of the related proteins has become one of the main 
targets for cervical cancer therapy to overcome the resistance developed by HPV 
oncoproteins (Baig et al., 2016).  
 
As we know, cervical cancer is a preventable disease. HPV vaccination 
has been introduced to control the disease. Yet, the vaccination has limited action as 
it has no therapeutic effect on pre-existing HPV even before the onset of cancer 
(World Health Organization, 2019).  Furthermore, a regular Papanicolaou smear (Pap 
smear) test can also provide an early detection for cervical cancer. However, women 
still lack the awareness about this medical screening (Lin, 2015). In terms of 
treatment aspects, radiotherapy and chemotherapy continue as the first line treatment 
against cervical cancer. Although these treatments have increased the long-term 




infertility and development of secondary cancer  (Derks et al., 2017; Manem et al., 
2017). Therefore, the searching for plant-based anti-cancer agent with comparable 
efficacy and less side effect may provide an alternative treatment against cervical 
cancer. 
 
Plants are a significant reservoir for therapeutic phytochemicals that 
serve promising intervention for cancer treatments. Plant-derived curative treatment 
provides the basis for most early medicines such as aspirin from willow trees and 
morphine from opium poppy plants (Kabera et al., 2014). Meant for clinically used 
anti-cancer drugs, vinca alkaloids were isolated from Catharanthus roseus, taxol 
from Taxus brevifolia and topotecan from Campthotheca acuminate (Butler, 2004; 
Manju et al., 2012; Khazir et al., 2014). In terms of cervical cancer treatment 
intervention, various plants were screened and numbers were scientifically proven to 
be able to combat this life-threatening cancer such as Quercus infectoria (Hazwani et 
al., 2018), Psidium guajava (Correa et al., 2016) Clinacanthus nutans (Mohd et al., 
2018) and Oroxylum indicum (Moirangthem et al., 2013; Siriwatanametanon et al., 
2010; Zazali et al., 2013).  
 
In this regards, O. indicum becomes one of the potential candidates to be 
developed as a new anti-cancer drug. O. indicum is a medium-sized tree, known as 
‘beko’ in Malaysia and can be eaten as vegetable (Zazali et al., 2013). Multiple 
studies have previously demonstrated the anti-cancer potentials of O. indicum in in 
vitro studies. O. indicum was found to exert cytotoxicity effects on a wide range of 
cancer cells such as human leukemia (Roy et al., 2007), human breast cancer 




hepatocarcinoma (Li et al., 2018) and human laryngeal carcinoma (Kamkaen et al., 
2006) cell lines. The pro-apoptosis potentials of O. indicum in cancer cells were 
observed through its anti-proliferative activities and morphological changes such as 
cell shrinkage, and reduction in size and shape of the O. indicum-treated cells (Zazali 
et al., 2013). These therapeutic capabilities are strongly associated with the 
abundance of its anti-cancer flavonoid content such as chrysin, oroxylin A and 
baicalein (Gao et al., 2016; Qiao et al., 2016; Xuan et al., 2016). 
 
1.2 Rationale of the study 
 
Despite government-led prevention approaches such as HPV vaccination 
and scheduled Pap smear screening, cervical cancer remained the third most 
diagnosed cancer among Malaysian women with approximately 2,000 new cases 
reported annually (Kessler, 2017; Manan et al., 2016; Mezei et al., 2017). Current 
chemotherapy methods offer the most effective treatment to treat cancer but the main 
disadvantage is the severe side effects (Mikkelsen et al., 2017; Muliira et al., 2017). 
Therefore, these limitations triggered the urge for the plant-derived anti-cancer agent 
development from ethnobotanical plants as an alternative.  
 
Based on the statements above, O. indicum becomes one of the most 
promising candidates to be exploited as a new anti-cancer drug due to its diverse 
distribution and promising anti-cancer properties (Kalra and Kaushik, 2017). 
Certainly, O. indicum was discovered to have the highest cytotoxicity to cancer cells 




Thai medicinal plants from prior reports (Costa-lotufo et al., 2005; 
Siriwatanametanon et al., 2010). 
Every part of O. indicum has been discovered to possess anti-
proliferative effects on cancer cells in vitro (Costa-lotufo et al., 2005; Kumar et al., 
2010; Moirangthem et al., 2013; Nagasaka et al., 2018; Rajkumar et al., 2011; 
Siriwatanametanon et al., 2010). The pro-apoptosis activities of this beneficial plant 
mainly contributed by its major compounds such as chrysin, oroxylin A and baicalein 
(Gokhale et al., 2017). Yet, only baicalein was selected to be investigated in this 
study. Baicalein is one of the major bioactive compounds that can be found 
abundantly in the leaves of O. indicum (Dinda et al., 2015). It is also a common 
flavonoid that can be isolated from Scutellaria baicalensis (Jianjun and Huiru, 2008) 
and Thymus vulgaris (Fujita et al., 2005). Anti-neoplastic effects of baicalein from 
other sources such as from S. baicalensis or synthetically produced were extensively 
studied in vitro in colon (Palko-Labuz et al., 2017; Taniguchi et al., 2008), 
promyelocytic leukemia (Li et al., 2004), ovarian (Chen et al., 2013a), hepatoma 
(Kuo et al., 2010; Zheng et al., 2014), oral (Cheng et al., 2012) and cervical (Yong et 
al., 2011) cancer cell lines. O. indicum’s baicalein exerted cytotoxic effects on 
bladder cancer (Yang et al., 2017), promyelocytic leukemia (Roy et al., 2007) and 
colorectal carcinoma cells (Lalou et al., 2013).  
 
Apart from that, baicalein was shown to be more a potent apoptosis 
inducer in cancer cells as compared to chrysin and oroxylin A (Parajuli et al., 2009; 
Sanoda et al., 2004). In a study done by Sanoda et al. (2004), the anti-proliferative 
activity of baicalein on human leukemia cells (HL-60) increased in a dose-dependent 




(Sanoda et al., 2004). On the other hand, higher percentage of apoptotic cells were 
detected in baicalein-treated malignant glioma cells as compared to chrysin-treated 
cells after 96 hours treatment period (Parajuli et al., 2009). From this finding, 
baicalein showed higher apoptotic activity rather than chrysin which make baicalein 
a better target to be studied. 
 
However, the knowledge regarding the anti-cancer activity of baicalein in 
cervical cancer is still limited. In SiHa and HeLa cervical cancer cells, baicalein was 
found to inhibit proliferation and induce cell cycle arrest at G0-G1 phase by 
inhibiting the phosphorylation of protein kinase B and glycogen synthase kinase 3ß 
that eventually caused the suppression of cyclin D1 (Wu et al., 2017). Indeed, 
baicalein acted as an apoptosis inducer in treated HeLa cells by alleviating the 
expression of important elements in extrinsic apoptosis pathway which were Fas, 
FasL as well as caspase-8 and subsequently increased the cell’s sensitivity towards 
apoptosis (Peng et al., 2015). The ability of baicalein to initiate apoptosis was also 
observed through the increment of apoptotic bodies formation in HeLa cells and 
tumour growth inhibition in mice bearing U14 cervical cancer following baicalein 
treatment (Peng et al., 2015; Yong et al., 2011). Due to this limited understanding on 
how baicalein induced apoptosis in cervical cancer model, the underlying mechanism 
related to pro-apoptosis activities of baicalein in HPV-associated cervical cancer 





1.3 Objectives of the study 
 
1.3.1 General objective 
 
1. To elucidate the mechanism of baicalein-rich fraction (BRF) from Oroxylum 
indicum on the apoptosis pathway in human cervical cancer cell lines; SiHa 
and HeLa. 
 
1.3.2 Specific objectives 
 
1. To isolate BRF from O. indicum leaves through bio-assay guided 
fractionation. 
2. To determine the anti-proliferative activity of BRF in human cervical cancer 
cell lines; SiHa and HeLa. 
3. To measure the expression of HPV oncoproteins (E6, E7), tumour suppressor 
proteins (p53, pRb) and proteins related in mitochondrial-mediated apoptosis 
pathway (Bax, Bcl-2, caspase-9 and caspase-3) in BRF-treated SiHa and 
HeLa cells. 
4. To determine the involvement of mitogen-activated protein kinase (MAPK) 
signalling in BRF-induced apoptosis in SiHa and HeLa cells.  
5. To measure the expression of cytokines; IL-6 and IL-12 in BRF-treated SiHa 








1.4.1 Null Hypothesis (H0) 
 
1. BRF from Oroxylum indicum does not affect the mechanism of apoptosis 
pathway in human cervical cell lines; SiHa and HeLa. 
 
1.4.2 Alternative hypotheses (H1) 
 
1. BRF will be fractionated from Oroxylum indicum leaves. 
2. BRF shows a potent anti-proliferativ activity in treated human cervical 
cancer cell lines; SiHa and HeLa. 
3. BRF-treated SiHa and HeLa cells will express low level of HPV 
oncoproteins and high level of apoptotic mediators as compared to the 
untreated cells. 
4. BRF’s activity in inducing cell death in SiHa and HeLa cells will be 
dependent on MAPK signaling cascade. 
5. SiHa and HeLa cells treated with BRF will express low level of IL-6 and 








2.1 Cervical cancer 
 
The word cervix originated from a Latin word meaning “neck,” 
representing its anatomical function as a narrow connection between the body of the 
uterus and the vagina as shown in Figure 2.1. This key component of the women’s 
reproductive system plays a crucial role in protecting the foetus during pregnancy 
and facilitating childbirth delivery (Myers et al., 2015). Stratified squamous 
epithelium that forms the first lining of cervix covers the mucus-secreting columnar 
epithelium of endocervix canal and the exocervix. The transition area between these 
types of cells that known as squamocolumnar junction was found to be the most 
susceptible point for viral evasion (Mirkovic et al., 2015). 
 
According to World Health Organization (WHO) (2019), cervical cancer 
is a slow-growing cancer that has developed in cervix tissues. It begins with the 
growth of abnormal cells on the cervix’s surface lining which also known as cervical 
intraepithelial neoplasia (CIN). As the time pass by, accumulation of the abnormal 
cells leads to the development of cancerous cells when the cells start to grow and 
spread deeply into the cervix. Cervical cancer signs and symptoms may include 
abnormal vaginal bleeding after sexual intercourse, irregular menstrual cycle, vaginal 



















Figure 2.1 The female reproductive system’s anatomic structure. The uterus, 
ovaries, fallopian tubes, cervix and vagina are among the organs in the female 
















2.1.2 Cervical cancer statistics 
 
Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2018 
showed cervical cancer as the fourth most frequently diagnosed cancer among 
women worldwide with 570,000 cases, and 311,000 deaths after breast cancer, 
colorectal cancer and lung cancer. Nevertheless, cervical cancer was second in 
incidence and mortality rates in less developed countries and third in transition 
countries (Bray et al., 2018). Despite that, cervical cancer leads the rank for new 
cases reported in 28 over 31 countries and based on the mortality profile, it is the 
leading cause of death in 42 countries including Sub-Saharan Africa and South 
Eastern Asia countries.  
 
Africa reported the highest regional incidence and mortality cases and 
this observation particularly contributed by cases from Southern Africa country 
(Swaziland), Western Africa countries (Guinea, Burkina Faso and Mali) and Eastern 
Africa countries (Malawi and Zimbabwe). Yet, the statistics are 10 times lower in the 
developed countries such as in Australia, North America, New Zealand and Western 
Asia countries such as Saudi Arabia (Bray et al., 2018). These facts demonstrate the 
negative relationship between cervical cancer incidence and mortality rates and 
country revenues, since cervical cancer cases have increased in low-income countries 
in comparison to developing and developed countries (Ng et al., 2015).   
 
As shown in Figure 2.2(a), cervical cancer ranked second among Asian 
women over top five common cancer in Asian countries. South Central Asian 




incidence of cervical cancer in Asia as India alone accounted for nearly 27% of the 
global incidence of cervical cancer as shown in Figure 2.2(b) (Ng et al., 2015). 
Within the Association of Southeast Asian Nations (ASEAN) countries, cervical 
cancer incidence was the second most reported for female-specific cancers with 44, 
351 cases after breast cancer (86, 842 cases) and followed by colorectal cancer (34, 
493 cases). It was ranked third in terms of mortality rates with 22, 473 deaths 
following breast cancer (36, 723 deaths) and lung cancer (27, 837 deaths) (Kimman 
et al., 2012). In this regard, most cervical cancer mortality was reported in 
Cambodia, followed by Myanmar, Thailand and Laos, as shown in Figure 2.3(a). The 
increase in cervical cancer incidence rates among ASEAN women has been observed 
with the increasing age when the chart is dominated by women older than 45 years 























































Figure 2.2 Cervical cancer in Asia. (a) Estimated age-standardised incidence of 
cervical cancer in the top five cancers (b) Regional estimated age-standardised 












































































Figure 2.3 Cervical cancer in ASEAN countries. (a) Regional-based estimated 
age-standardised mortality rate (b) Age-based cancer incidence rate per 100,000 








Meanwhile in Malaysia, cervical cancer is the third most common cancer 
among Malaysian women with an incidence rate of 19.7 per 100,000 women and the 
seventh among total cancer cases reported across the general population (Manan et 
al., 2016). About 4, 325 cases were reported in between 2007-2011 which 
contributed 9.7% from total cancer cases for top ten diagnosed cancer in Malaysia 
with most of the cases were reported in Sarawak and least in Kelantan (Figure 
2.4(a)). The incidence rate of cervical cancer was started to be detected in 25 years 
old women and reached the peak at the age of 70-74 years old as shown in Figure 
2.4(b). Literally, no cases were reported for women under the age of 24, but it is the 
second common cancer for 25 to 59 years old women, and the fourth for women 
aged 60 to 74. By ethnicity, it ranked fourth among Malay, third among Chinese, 
third among Indian and second among other Bumiputera ethnics (Manan et al., 
2016). The highest incidence rate of cervical cancer was detected in Chinese 
population (9.8), followed by Indian community (7.6) and Malay (5.1) per 100, 000 











































Figure 2.4 Cervical cancer in Malaysia. (a) Regional-based estimated age-
standardised incidence rate (b) Age-based cancer incidence rate per 100,000 
























2.2 Causative agent of cervical cancer 
 
Cervical cancer is a multifactorial cancer (Figure 2.5). Unhealthy sexual 
behaviors such as high parity and first intercourse at a very young age (under 15 
years old) elevate the risk of cancer development as 54% of reported cases in India 
involved with two or more parity. India is one of the countries with the highest 
number of cervical cancer cases worldwide (Nath et al., 2015). Besides, 
immunosuppressed patients with low counts of CD4+ T cells especially for women 
infected with human immunodeficiency virus (HIV) were found to be an important 
enhancer for cervical carcinogenesis as HIV also induced systemic natural killer 
(NK) and T cells defects in patients (Bere et al., 2014; Clifford et al., 2016). On the 
other hands, epidemiological studies persistently associating the period of smoking 
with the progression of invasive cervical cancer as tobacco content in the smoke 
provided a favourable condition for malignancies through induction of oxidative 
stress and deoxyribonucleic acid (DNA) damage (Appleby et al., 2006; Carnevale et 
al., 2016; de Marco, 2013; Roura et al., 2014). Tobacco by-products and 
carcinogenic chemiscals in cigarettes found in the cervical mucosa of smoking 
women supported the potential for cervical cancer (Kessler, 2017).  
 
Despite all these risk factors, a strong and specific association relating 
human papillomavirus (HPV) with cervical cancer was shown beyond any 
reasonable doubt by consistent evidences from epidemiological studies (Clifford et 
al., 2003; de Martel et al., 2017; Hu et al., 2015). HPV-DNA was detected in 90-
100% of cervical cancer cases in investigated population by using state-of-the-art 
amplification techniques in clinical and epidemiological studies (de Martel et al., 
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Figure 2.5 Natural history of cervical cancer development. Unhealthy sexual activities and other co-founding risk factors elevate the 




2.2.1 Human papillomavirus (HPV) 
 
HPV belongs to Papillomaviridae family, small size and double stranded 
DNA virus. Up to date, more than 200 types of HPV have been identified based on 
their common DNA sequence and about 40 of it were implicated with genital 
infections (de Martel et al., 2017). HPV can be classified into several groups based 
on its associated diseases ranging from innocuous lesions to its ability in inducing 
malignant transformation in the cells of infected host (Table 2.1). Infection with low-
risk HPV types results in the proliferation of epithelial cells and typically manifested 
as papillomas or benign warts on the skin (Sanjose et al., 2018). Yet, these infections 
are self-limiting and rarely associated with malignancies.  
 
In contrast, persistent infection of high-risk HPV types can lead to 
cancerous development as proven by the detection of all 15 HPV types in HPV-
related cervical carcinoma cases (Clifford et al., 2003; Mirkovic et al., 2015). HPV 
16 and HPV 18 were the most prevalent high-risk HPV types identified in multistage 
carcinogenesis of cervical cancer reported worldwide as demonstrated in Figure 2.6 
(de Martel et al., 2017) and the same trend of HPV distribution also detected in 
Asian countries (Bao et al., 2008) including Malaysia (Raub et al., 2014; Tan et al., 
2018).  
 
Persistent infection of HPV 16 integration was significantly associated 
with malignant progression, with increased frequency from pre-neoplastic lesions to 
invasive tumors. From a study done by Badaracco et al., (2002), HPV 16 DNA was 




HPV 18 showed pure integrated forms (Badaracco et al., 2002). Nevertheless, the 
complete HPV 18 integration indicates a different behaviour in genital 
transformation compared to HPV 16 and may reflect a major aggressiveness of this 
viral type. It is suggested that HPV 18 causes a greater chromosome instability 
compared to HPV 16 that may in turn explain the major pathogenetic role of HPV 18 
in term of aggressiveness (Shima et al., 2000). 
 
Table 2.1 Classification of HPV types. Summarised from Bathula et al., (2015). 
Group HPV type 
High-risk 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 
82 
Probable high- risk 26, 53, 66 
Low-risk 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 



































Figure 2.6 Distribution of HPV genotypes reported throughout the world in 




2.2.1(a) Genetic structure of HPV 
 
The HPV genome exists as a covalently closed circle that consists of 
approximately 8000 base pairs of double-stranded circular DNA associated with 
histones (Doorbar et al., 2012). The genomic structure of HPV is divided into three 
regions depending on its expression time and their particular functions in controlling 
the replication of viral genetic materials (Figure 2.7). The three regions are consist of 
non-coding long control region (LCR), early region (E) and late region (L) (Yuan et 
al., 2012). LCR contains p97 and p670 core promoters that include enhancer and 
silencer sequences that are responsible for regulating the transcription of the early 
and late region respectively.  
 
Meanwhile, the early region of the HPV genome encoded for non-
structural proteins (E1, E2, E4, E5, E6 and E7) is transcribed early in the infection 
phase and responsible for modulating keratinocyte differentiation, promoting viral 
evasion from the host immune system and accelerating the replication of viral DNA. 
(Sanjose et al., 2018). The expression of early gene products is therefore a crucial 
factor in the malignant transformation of host cells (Kranjec and Doorbar, 2016). In 
the meantime, the structural proteins encoded in the late-expressed region, L1 and 
L2, play a central role in forming the viral capsid and assembling the virus particles. 
L1 is the primary structural element of the virus coat proteins containing infectious 
virions made up of 72 capsomeres carrying 360 protein copies (Mirkovic et al., 
2015). Table 2.2 summarises the general functions for each encoded HPV protein. 
  
